Project Oncology®

While intrinsic mutations, like PIK3CA, are present at the outset and can be identified upfront in patients with HR+/HER2- metastatic breast cancer, acquired mutations, like ESR1, cannot be detected on baseline tumor profiling. That’s why longitudinal monitoring with liquid biopsies over the course of treatment is required. Learn more about these key differences in testing for acquired versus intrinsic mutations with Dr. Megan Kruse, a breast medical oncologist at the Cleveland Clinic.

Breast cancer is the second most common cause of brain metastases. Given this prevalence, how can we identify the early signs and symptoms and treat patients with metastatic breast cancer accordingly? Here to dive further into this topic with Dr. Pavani Chalasani is Dr. Jose Pablo Leone, Director of the Program for Breast Cancer in Men at Dana-Farber.

Not only can biosimilars impact the health of our patients with cancer, but they can also contribute to cost savings for the healthcare system as a whole. Here to dive further into the economic impacts of biosimilars in the oncology space with Dr. Mary Katherine Cheeley is Dr. Sophia Humphreys, Director of System Pharmacy Formulary Management and Clinical Programs at Sutter Health.

Bone metastases are the most frequent site of metastatic spread for breast cancer, especially for the luminal subtypes, which are the most frequent types of breast cancer. Here to dive further into these therapies with Dr. Pavani Chalasani is Dr. Gabriel Hortobagyi, Professor of Medicine in the Department of Breast Medical Oncology in the Division of Cancer Medicine at the University of Texas, MD Anderson Cancer Center in Houston.

How can ribociclib plus endocrine therapy help reduce recurrence in early breast cancer? That’s the exact question the NATALEE trial sought to answer, and here to discuss the results with Dr. Pavani Chalasani is Dr. Nicholas McAndrew, Assistant Professor in the Division of Hematology and Oncology at the UCLA David Geffen School of Medicine.

NUT carcinoma is a rare, aggressive form of cancer that’s highly resistant to therapy and has no defined standard treatment. Joining Dr. Jacob Sands to discuss the best diagnostic and treatment strategies for NUT carcinoma is Dr. Jia Luo, medical oncologist at Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School in Boston.

In a recent study, investigators conducted a randomized trial to compare the efficacy and tolerability of a fixed dose of an oral chemotherapy drug on a 7/7 schedule. Here with Dr. Pavani Chalasani to discuss the results from the X-7/7 trial is Dr. Colleen Bohnenkamp, Oncology Clinical Pharmacist who specializes in women’s cancers at the University of Kansas Cancer Center.

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss advances in molecular profiling and classification of AML, as well as the newest approved treatments.

Uterine cancer is the most common type of gynecologic malignancy in the United States, and disease mortality is on the rise. What do we need to know from recent studies to diagnose patients earlier? Take a deep dive with Dr. Charles Turck as he is joined by Dr. Richard Penson, Medical Oncologist specializing in Gynecologic Oncology at Massachusetts General Hospital in Boston.

Brain metastases are the most common type of brain tumor, and unfortunately, prognosis is still limited and can range from a few months to a few years. However, the next-step approaches look promising for improving patient outcomes. Dive in with Dr. Charles Turck as he speaks with Dr. Priscilla Brastianos, Associate Professor of Medicine at Harvard Medical School and the Director of the Central Nervous System Metastasis Center at Massachusetts General Hospital.

This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

A recent survey conducted by physicians at Penn Medicine found that one-third of female oncologists reported experiencing infertility. Join Dr. Emily Macduffie, Radiation Oncology Resident Physician at Penn Medicine, as she speaks about potential solutions related to infertility for women in medicine based on her 2023 ASCO presentation.

Cancer occurs in approximately 1 in every 1,000 pregnant patients and requires complex solutions from a multidisciplinary team. Learn more about the expanding management options for these patients with Dr. Alison Loren, Chief of the Division of Hematology and Oncology at the University of Pennsylvania Perelman School of Medicine.

Over the past few decades, increasing attention has been placed on reducing the risk of patient harm within the healthcare system. Learn more about the risks that are specific to medical oncology and how current systems are addressing them with Dr. Jacob Sands and Dr. Joseph Jacobson, Senior Advisor for Quality and Patient Safety at Dana-Farber Cancer Institute.

Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.

From disease-related factors to the latest clinical trial data, there’s a lot to consider when selecting a therapy for patients with ER+/HER2- metastatic breast cancer. Here with Dr. Charles Turck to break down the key factors that can guide our treatment selections is breast medical oncologist Dr. Megan Kruse from the Cleveland Clinic in Ohio.

Obstacles with platinum rechallenge could lead to treatment burden, but a second-line alternative therapy could be a better option for some of our patients. To learn more, Dr. Charles Turck is joined by Drs. Jacob Sands and Joshua Sabari to share their insights on this therapy for patients with small cell lung cancer.

Treatment for lung cancer can be complex, but PL-L1 expression and tumor mutational burden might help us select the best treatment for our patients. What do we need to know about the role of these biomarkers in the treatment of lung cancer? To discuss this, Dr. Jacob Sands is joined by Dr. Biagio Ricciuti, a medical oncologist at the Dana-Farber Cancer Institute.

Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.